02186 綠葉製藥
公司背景| 業務概覽| 企業架構| 基本數據| 財務比率| 損益表| 財務狀況表| 現金流量表| 派息紀錄| 盈利預測| 股權變動| 股票賣空
公司資料 - 股權變動
股權披露
配股集資
公司回購
日期 股東名稱 披露原因 買入／賣出涉及
的股份數目		 每股平均價 持有權益的
股份數目		 佔已發行
股本(%)
10/09/2025刘殿波1213(L)
1213(S)		1,246,108,703(L)
212,229,950(S)		31.20
5.31
10/09/2025LuYe Pharmaceutical International Co., Ltd.1213(L)
1213(S)		1,246,108,703(L)
212,229,950(S)		31.20
5.31
10/09/2025Ginkgo (PTC) Limited1213(L)
1213(S)		1,246,108,703(L)
212,229,950(S)		31.20
5.31
10/09/2025LuYe Pharmaceutical Investment Co., Ltd.1213(L)
1213(S)		1,246,108,703(L)
212,229,950(S)		31.20
5.31
10/09/2025UBS Group AG1213(L)475,390,688(L)
480,663,190(S)		11.90
12.03
10/09/2025Hillhouse Investment Management, Ltd.1213(L)552,324,108(L)13.83
10/09/2025Hillhouse Fund V, L.P.1213(L)552,324,108(L)13.83
10/09/2025NEV Holdings Limited1213(L)552,324,108(L)13.83
10/09/2025Luye Life Sciences Group Ltd1213(L)
1213(S)		1,246,108,703(L)
212,229,950(S)		31.20
5.31
10/09/2025Shorea LBG1213(L)
1213(S)		1,246,108,703(L)
212,229,950(S)		31.20
5.31
10/09/2025Nelumbo Investments Limited1213(L)
1213(S)		1,246,108,703(L)
212,229,950(S)		31.20
5.31
10/09/2025Luye Pharma Holdings Ltd.1213(L)
1213(S)		1,246,108,703(L)
212,229,950(S)		31.20
5.31
09/09/2025LuYe Pharmaceutical International Co., Ltd.1213(L)
1213(S)		1,246,108,703(L)
212,229,950(S)		31.61
5.38
09/09/2025刘殿波1213(L)
1213(S)		1,246,108,703(L)
212,229,950(S)		31.61
5.38
09/09/2025LuYe Pharmaceutical Investment Co., Ltd.1213(L)
1213(S)		1,246,108,703(L)
212,229,950(S)		31.61
5.38
09/09/2025Nelumbo Investments Limited1213(L)
1213(S)		1,246,108,703(L)
212,229,950(S)		31.61
5.38
09/09/2025Ginkgo (PTC) Limited1213(L)
1213(S)		1,246,108,703(L)
212,229,950(S)		31.61
5.38
09/09/2025Luye Life Sciences Group Ltd1213(L)
1213(S)		1,246,108,703(L)
212,229,950(S)		31.61
5.38
09/09/2025Luye Pharma Holdings Ltd.1213(L)
1213(S)		1,246,108,703(L)
212,229,950(S)		31.61
5.38
09/09/2025Shorea LBG1213(L)
1213(S)		1,246,108,703(L)
212,229,950(S)		31.61
5.38
08/09/2025RRJ Capital Master Fund IV, L.P.1704(L)-33,000,000(L)HKD 3.849(L)190,584,583(L)4.90
08/09/2025Ong Tiong Sin1704(L)-33,000,000(L)HKD 3.849(L)190,584,583(L)4.90
08/09/2025Kale Asset Holding Ltd1704(L)-33,000,000(L)HKD 3.849(L)190,584,583(L)4.90
08/09/2025RRJ Capital IV Ltd1704(L)-33,000,000(L)HKD 3.849(L)190,584,583(L)4.90
05/09/2025UBS Group AG1305(L)33,142,964(L)472,356,964(L)
481,303,244(S)		12.15
12.38
04/09/2025RRJ Capital IV Ltd1201(L)-10,000,000(L)HKD 3.800(L)229,813,583(L)5.91
04/09/2025Kale Asset Holding Ltd1201(L)-10,000,000(L)HKD 3.800(L)229,813,583(L)5.91
04/09/2025RRJ Capital Master Fund IV, L.P.1201(L)-10,000,000(L)HKD 3.800(L)229,813,583(L)5.91
04/09/2025UBS Group AG1306(L)20,903,889(L)468,569,466(L)
481,897,246(S)		12.05
12.39
04/09/2025Ong Tiong Sin1201(L)-10,000,000(L)HKD 3.800(L)229,813,583(L)5.91
03/09/2025UBS Group AG1305(L)30,911,088(L)469,665,964(L)
485,806,744(S)		12.08
12.49
02/09/2025UBS Group AG1101(L)+6,732,000(L)HKD 3.795(L)468,669,018(L)
484,298,070(S)		12.05
12.45
29/08/2025UBS Group AG1306(L)34,433,806(L)457,471,387(L)
480,498,558(S)		11.76
12.36
28/08/2025UBS Group AG1306(L)30,493,214(L)458,526,444(L)
481,751,115(S)		11.79
12.39
25/08/2025UBS Group AG1306(L)19,712,080(L)455,167,154(L)
483,072,509(S)		11.70
12.42
22/08/2025Ong Tiong Sin1201(L)-6,599,500(L)HKD 3.766(L)271,823,083(L)6.99
22/08/2025RRJ Capital Master Fund IV, L.P.1201(L)-6,599,500(L)HKD 3.766(L)271,823,083(L)6.99
22/08/2025Kale Asset Holding Ltd1201(L)-6,599,500(L)HKD 3.766(L)271,823,083(L)6.99
22/08/2025RRJ Capital IV Ltd1201(L)-6,599,500(L)HKD 3.766(L)271,823,083(L)6.99
21/08/2025UBS Group AG1305(L)19,712,110(L)450,756,512(L)
479,169,770(S)		11.59
12.32
  1    2   3    4    5    6    7    8    9  
備註： (L) - 長倉：包括 (1) 持有股份；(2) 透過持有、沽出或發行金融合約，有權或有責任購買相關股份。
  (S) - 短倉：包括 (1) 借入股份；(2) 透過持有、沽出或發行金融合約，有權或有責任沽出相關股份。
  (P) - 可供借出的股份
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.